Dynavax Technologies Corporation (DVAX)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	27,309	20,478	17,177	9,222	-6,389	61,125	110,641	235,965	293,025	325,071	232,832	108,217	76,310	-38,936	-6,105	-61,824	-75,240	-96,529	-134,389	-125,523
Total stockholders’ equity	US$ in thousands	596,799	681,427	642,849	618,480	622,072	604,916	577,205	563,732	581,013	500,576	422,799	287,484	222,374	67,576	83,380	99,762	58,693	69,284	58,295	11,824
ROE		4.58%	3.01%	2.67%	1.49%	-1.03%	10.10%	19.17%	41.86%	50.43%	64.94%	55.07%	37.64%	34.32%	-57.62%	-7.32%	-61.97%	-128.19%	-139.32%	-230.53%	-1,061.60%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $27,309K ÷ $596,799K
= 4.58%

Dynavax Technologies Corporation's return on equity (ROE) has exhibited a notable improvement over the past few years. The company's ROE was deeply negative in early 2020, reaching as low as -1,061.60% in March 2020. However, there has been a consistent positive trend since then, with ROE gradually increasing quarter by quarter.

By the end of 2021, the company had successfully turned around its ROE, achieving a positive figure of 34.32%. This positive momentum continued into 2022 and 2023, with further increases in ROE reported each quarter.

As of December 31, 2024, Dynavax Technologies Corporation's ROE stands at a healthy 4.58%, reflecting the company's efforts to enhance its profitability and efficiency in utilizing shareholder equity to generate returns. The consistent improvement in ROE indicates that the company has been effectively leveraging its equity capital to drive shareholder value and profitability.